Short answer
Bio-Techne (TECH) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). References February 11, 2026 Form 8-K for officer appointments and compensation arrangements.
Bio-Techne 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- References February 11, 2026 Form 8-K for officer appointments and compensation arrangements
- Executive and director ownership changes reported through SEC Forms 3 or 4
- Proxy materials expected to disclose transaction participants and their security interests
Item 8.01 · Other Events
- Merck merger remains subject to shareholder approval at September 23, 2026 special meeting
- Shareholder lawsuit seeks to enjoin the vote, alleging proxy omissions; multiple demand letters create execution risk
- Supplemental disclosures reveal 2023 Merck indications at $92–$95 per share versus Bio-Techne trading at $73.76–$85.98
- Goldman Sachs valuation updates show illustrative present values of $58–$72 per share and reference values of $49–$67
- Disclosed valuation inputs include $200 million debt, $210 million cash, $421 million LTM adjusted EBITDA, and 17.5x–24.5x multiples
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bio-Techne 8-K filings
Get the next TECH 8-K as it lands
Follow TECH for push alerts, or ask the research agent what this filing means.